Shares of Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) have received an average recommendation of "Buy" from the seven ratings firms that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $18.60.
Several equities research analysts have issued reports on the stock. Leerink Partnrs upgraded shares of Atyr PHARMA to a "strong-buy" rating in a research note on Tuesday, February 18th. Leerink Partners started coverage on shares of Atyr PHARMA in a research note on Tuesday, February 18th. They set an "outperform" rating and a $16.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Atyr PHARMA in a report on Friday, March 14th. Finally, Cantor Fitzgerald initiated coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They set an "overweight" rating on the stock.
Check Out Our Latest Research Report on ATYR
Atyr PHARMA Price Performance
Shares of NASDAQ ATYR traded up $0.23 during midday trading on Wednesday, reaching $2.97. 2,188,219 shares of the company traded hands, compared to its average volume of 895,516. The stock's 50-day simple moving average is $3.46 and its 200-day simple moving average is $3.27. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA has a 12 month low of $1.42 and a 12 month high of $4.66. The firm has a market cap of $263.91 million, a PE ratio of -3.16 and a beta of 0.95.
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. As a group, equities analysts anticipate that Atyr PHARMA will post -0.91 earnings per share for the current fiscal year.
Institutional Trading of Atyr PHARMA
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ATYR. Jefferies Financial Group Inc. bought a new stake in shares of Atyr PHARMA in the 4th quarter valued at $201,000. Alpine Global Management LLC acquired a new position in shares of Atyr PHARMA in the 4th quarter valued at about $63,000. Woodline Partners LP bought a new stake in shares of Atyr PHARMA during the 4th quarter valued at about $6,092,000. Squarepoint Ops LLC acquired a new stake in Atyr PHARMA during the fourth quarter worth approximately $96,000. Finally, Two Sigma Advisers LP acquired a new stake in Atyr PHARMA during the fourth quarter worth approximately $44,000. Institutional investors and hedge funds own 61.72% of the company's stock.
Atyr PHARMA Company Profile
(
Get Free ReportaTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Featured Stories
Before you consider Atyr PHARMA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atyr PHARMA wasn't on the list.
While Atyr PHARMA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
